Fed. Circ. Revives Merck Suit Over Temodar Patent
A federal appeals court has overturned a lower court's decision that a Merck & Co. Inc. patent for brain tumor treatment Temodar is unenforceable, dealing a blow to defendant Barr Pharmaceuticals...To view the full article, register now.
Already a subscriber? Click here to view full article